^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    RZ-001

    i
    Other names: RZ-001
    Company:
    Rznomics
    Drug class:
    TERT inhibitor
    Related drugs:
    12ms
    A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination with Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects with Hepatocellular Carcinoma (clinicaltrials.gov)
    P1/2, N=45, Recruiting, Rznomics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • RZ-001 • Valcyte (valganciclovir)
    1year
    A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination with Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects with Hepatocellular Carcinoma (clinicaltrials.gov)
    P1/2, N=45, Not yet recruiting, Rznomics, Inc.
    New P1/2 trial • Combination therapy
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • RZ-001 • Valcyte (valganciclovir)
    1year
    Expanded Access Program for GBM Subjects (clinicaltrials.gov)
    P=N/A, N=0, Temporarily Not Available, Rznomics, Inc.
    New trial • Combination therapy
    |
    RZ-001 • Valcyte (valganciclovir)
    1year
    A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 with Valganciclovir (VGCV) in Subjects with Hepatocellular Carcinoma (clinicaltrials.gov)
    P1/2, N=42, Active, not recruiting, Rznomics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy
    |
    TERT (Telomerase Reverse Transcriptase)
    |
    RZ-001 • Valcyte (valganciclovir)
    over1year
    A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma (clinicaltrials.gov)
    P1/2, N=43, Recruiting, Rznomics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    TERT (Telomerase Reverse Transcriptase) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • IL10 (Interleukin 10)
    |
    RZ-001 • Valcyte (valganciclovir)
    2years
    A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma (clinicaltrials.gov)
    P1/2, N=43, Not yet recruiting, Rznomics, Inc.
    New P1/2 trial • Combination therapy
    |
    TERT (Telomerase Reverse Transcriptase)
    |
    RZ-001 • Valcyte (valganciclovir)
    3years
    A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Hepatocellular Carcinoma (clinicaltrials.gov)
    P1/2, N=42, Recruiting, Rznomics, Inc.
    New P1/2 trial • Combination therapy
    |
    TERT (Telomerase Reverse Transcriptase)
    |
    RZ-001 • Valcyte (valganciclovir)